Genomic Health, Inc. (GHDX) Receives Consensus Recommendation of “Hold” from Analysts
Genomic Health, Inc. (NASDAQ:GHDX) has been given a consensus rating of “Hold” by the ten ratings firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $31.83.
A number of research firms have weighed in on GHDX. Jefferies Group LLC reaffirmed a “hold” rating and set a $33.00 target price on shares of Genomic Health in a research note on Monday, June 12th. Canaccord Genuity decreased their target price on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 15th. BidaskClub cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $31.00 target price on shares of Genomic Health in a research note on Thursday, August 3rd. Finally, Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/09/25/genomic-health-inc-ghdx-receives-consensus-recommendation-of-hold-from-analysts.html.
In other news, CEO Kimberly J. Popovits sold 1,468 shares of Genomic Health stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $32.67, for a total transaction of $47,959.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $31.86, for a total transaction of $159,300.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,642 shares of company stock worth $1,343,081. 46.20% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of GHDX. Teachers Advisors LLC lifted its holdings in shares of Genomic Health by 6.1% during the fourth quarter. Teachers Advisors LLC now owns 31,801 shares of the medical research company’s stock worth $935,000 after purchasing an additional 1,838 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Genomic Health by 25.4% during the first quarter. Russell Investments Group Ltd. now owns 24,322 shares of the medical research company’s stock worth $766,000 after purchasing an additional 4,925 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Genomic Health by 0.6% during the first quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock worth $2,789,000 after purchasing an additional 500 shares during the period. Airain ltd acquired a new position in shares of Genomic Health during the first quarter worth $285,000. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of Genomic Health by 13.6% during the first quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock worth $259,000 after purchasing an additional 993 shares during the period. Institutional investors own 88.90% of the company’s stock.
Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The company had revenue of $85.50 million for the quarter, compared to the consensus estimate of $86.08 million. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.18) EPS.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.